Fergie by Wet ‘n Wild nail color collection hits stores
LOS ANGELES — Beauty brand Wet ‘n Wild took 2012 by storm by signing international pop culture icon Fergie as its first ever global beauty ambassador and has now announced the launch of the first line from the collaboration. Enter Fergie by Wet ‘n Wild nail color collection.
The Fergie by Wet ‘n Wild nail color collection features 24 shades developed in partnership with the superstar. Each shade is inspired by and dubbed by the Dutchess herself with names like Fergalicious, Grammy Gold and Tonight’s Gonna Be A Good Night and range from red carpet glam to funky and hip.
This collection will be available at mass for $3.49 beginning in September.
Anheuser-Busch donates emergency drinking water to Hurricane Isaac relief efforts
ST. LOUIS — Anheuser-Busch has shipped 4,312 cases of emergency drinking water — or 103,488 cans — to areas that were affected by Hurricane Isaac.
The company said the water has been made available to communities and relief organizations assisting impacted residents. Anheuser-Busch has donated more than 71 million cans of emergency drinking water following natural and other disasters since 1988.
"Relief workers and people in the region are in need of emergency drinking water, and this is one way we helped alleviate the immediate needs in the affected communities," Anheuser-Busch VP supply Peter Kraemer said.
Impax settles with Genzyme over kidney dialysis drugs
HAYWARD, Calif. — Generic drug maker Impax Labs has settled with a subsidiary of Sanofi regarding generic versions of two drugs for dialysis patients, Impax said Tuesday.
Impax announced a settlement with Genzyme concerning generic versions of Renvela (sevelamer carbonate) 800 mg tablets and 2.4 g and 0.8 g oral suspension and Renagel (sevelamer hydrochloride) tablets in the 400 mg and 800 mg strengths.
Under the settlement, Impax will have a license to sell its generic versions of the drugs on Sept. 16, 2014, or possibly earlier. Impax said it was likely the first company to file a complete regulatory approval application with the Food and Drug Administration for versions of both drugs, which are used to control serum phosphorus in patients with chronic kidney disease on dialysis. If it is, then it would be entitled to 180 days of market exclusivity in which to compete directly with the branded versions upon receiving FDA approval.
Renagel and Renvela had sales of $512 million between April 1, 2011 and the end of 2011 and $392 million in the first half of 2012, according to Sanofi.